SecBot SecBot
PRESS-RELEASE ·Filed Nov 6, 2026

ACRV

Acrivon Therapeutics, Inc
NEUTRAL
Impact 4/10
Horizonweeks Processed10d 17h ago WireGlobeNewswire
Press release · M&A
Actionable Insight • Neutral

Monitor the November 10 webcast for KOL commentary on ACR-525's potential in EoE and IBD. The undisclosed deal size and lack of financial terms limit immediate valuation read-through; watch for any subsequent financing or cash position update.

DirectionNeutral
Confidencemedium
Horizonweeks

ACR-525

● Neutral Named in this press release
Impact
Phase
Phase 2-ready (Phase 1 completed)
Time to market
ACR-525 is Phase 2-ready but has not yet initiated a Phase 2 trial. Assuming successful development, an approval in EoE would likely be several years away (3-5+ years minimum).
Next catalyst
None dated

What to watchWatch the November 10 KOL webcast for clinical development strategy and the November 12 Q3 earnings call for cash position updates. The undisclosed acquisition cost makes it hard to assess the financial impact on Acrivon's ~$75M market cap company. Any subsequent financing or partnership announcement would be a key signal.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.61
T+0 close · Nov 6, 2026 · via day close
Latest settled
−9.94%
T+5 · $1.45
Vs SPY
−12.53%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $1.61entry
  2. T+1 · 8d ago −1.86%α −4.23% · $1.58
  3. T+5 · 4d ago −9.94%α −12.53% · $1.45
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Acrivon Therapeutics acquired ACR-525 (Phase 2-ready oral JAK1 inhibitor) and a preclinical PKCθ inhibitor program from Aqilion AB for an undisclosed cash consideration, with no future royalties or milestones. The deal establishes immunology and inflammation as a new strategic pillar alongside oncology, targeting eosinophilic esophagitis as the first indication. The transaction closed concurrently with signing and was approved by both companies' boards.

Key Facts

  • Acrivon acquired ACR-525 (Phase 2-ready oral JAK1 inhibitor) and a preclinical PKCθ inhibitor program from Aqilion AB.
  • Consideration was undisclosed cash with no future royalties or milestone obligations.
  • Eosinophilic esophagitis (EoE) targeted as first potential indication using a Phase 2-ready formulation.
  • Transaction closed concurrently with signing; approved by both boards.
  • Acrivon's market cap is $75M; no deal value disclosed.
  • Company to host webcast on November 10, 2026.

Financial Impact

Undisclosed cash consideration; no deal value stated. Acrivon's market cap is $75M.

cashpipeline

Risk Factors

  • Undisclosed deal value creates uncertainty about cash burn and potential dilution.
  • ACR-525 is Phase 2-ready but has not yet demonstrated efficacy in EoE; clinical risk remains high.
  • Integration of I&I pipeline may require additional expertise and resource allocation.
  • No future royalties or milestones means full upside retained but also full development cost borne by Acrivon.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3397471

Track record

8 reports on ACRV

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today Press Release Neutral 4/10 Entry $1.45 Now $1.46 +0.69% settles Feb 16
  2. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.57 Now $1.46 −7.01% settles Feb 9
  3. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $1.61 Now $1.46 −9.32% settles Feb 4
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Viewing Entry $1.61 Now $1.46 −9.32% settles Feb 4
  5. Jul 21, 202616w ago Press Release Neutral 3/10 Entry $1.68 to $1.76 Now $1.46 −13.10% ▲ +4.76% +1.50% vs SPY
  6. May 22, 202625w ago DEFA14A Neutral 3/10 Entry $1.67 to $2.39 Now $1.46 −12.57% ▲ +43.11% +40.39% vs SPY
  7. Apr 30, 202628w ago DEFA14A Neutral 2/10 Entry $1.85 to $1.56 Now $1.46 −21.08% ▼ −15.68% −18.78% vs SPY
  8. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $1.70 to $1.52 Now $1.46 −14.12% ▼ −10.59% −24.93% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 8h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026